

## South Carolina Statistics

### PCSK9 Inhibitors



### About PCSK9 Inhibitors

PCSK9 inhibitors are designed for patients with extremely high LDL, or “bad,” cholesterol. The drugs are approved by the Food and Drug Administration to treat:

- **Heterozygous familial hypercholesterolemia**, an inherited condition that causes high levels of LDL cholesterol
- **Clinical atherosclerotic cardiovascular disease**, such as heart attacks or strokes.

### Analysis of Health Plan Coverage & Access

A national data supplier reviewed PCSK9 inhibitor claims for managed care organizations in South Carolina from January 2017 through December 2017.

#### Key South Carolina Findings



Rejection Rate:

**29%**



Appeals Rate:

**31%**



Final Rejections:

**1,182**

Of health plans that received at least 50 claims for PCSK9 inhibitors, the following had **the highest rates of rejections:**

- Tricare Military Health Svc Sys **59%**
- BCBS South Carolina **54%**
- Express Scripts **52%**
- CVS Health **40%**

The following had **the lowest rates of rejection:**

- Aetna **12%**
- Humana Health Plan **11%**



The following table details claims data for the South Carolina managed care organizations that received at least 50 claims for PCSK9 inhibitors.

Managed Care Organization	Rejection %	Total Claims	Rejections
Tricare Military Health Svc Sys	59%	141	83
BCBS SC	54%	302	163
Express Scripts	52%	155	81
CVS Health	40%	378	150
South Carolina Public Employee Benefit Authority	31%	426	134
United Health Group	24%	697	167
Wellcare Management Group	24%	55	13
Cigna Healthcare	17%	184	31
Aetna	12%	346	41
Humana Health Plan	11%	980	107

*Data source: National data supplier; Medicare, Medicaid, Medicaid managed care, and commercial plans; January-December 2017.*



The Institute for Patient Access is a physician led nonprofit 501(c)(3) research organization promoting the benefits of the physician-patient relationship in the provision of quality healthcare.

